Floatz logo

Mefloquine

Malaria

London School of Hygiene and Tropical MedicineSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Malaria cohort.

Asset / SponsorPhaseRating
Artesunate
University of Khartoum
Phase 4BBB
COA566
Novartis
Phase 4BB
Hydroxyurea
Indiana University
Phase 3BB
Quinine
University of Khartoum
Phase 4BB
ama1-c1
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1/2B

View all 13 →

Same molecule, other indications

Mefloquine is also rated in:

Sickle Cell CrisisDormant
CCC
Indicative ·
52 / 100
View asset →
gliosarcomaDormant
CC
Indicative ·
41 / 100
View asset →
glioblastomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →